Zai Lab (ZLAB) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Key milestones and financial performance

• Achieved commercial profitability in 2023, with strong 48% year-over-year revenue growth in Q3 2024 and a 40% reduction in losses.

• Expect overall corporate profitability by Q4 2024 or Q4 2025, supported by $330 million to ~$930 million in cash reserves.

• Projecting 40% year-over-year revenue growth for 2024 and targeting $2 billion in annual revenue by 2028.

• Margins improved from under 10% in 2022 to 37% in Q3 2024, with further gains expected from new product launches and local manufacturing.

• R&D expenses expected to remain flat in 2025, with capacity to reinvest in global pipeline as regional assets mature.

Pipeline and product development

• Lead global asset ZL-1310, a DLL3 ADC, is in pivotal stage with NDA/BLA submission to FDA targeted for 2026-2027.

• Three new IND submissions planned for 2024-2025: ZL-6301 (ROR1 ADC), ZL-6201 (LRRC15 ADC), and ZL-1503 (bispecific/IL31xIL13).

• Multiple in-house global assets expected to reach pivotal or proof-of-concept data points by 2027-2028.

• Ongoing basket trials for DLL3 in neuroendocrine tumors and dose optimization in small cell lung cancer.

• Collaboration with Vertex on povetacicept for IgAN, leveraging synergy with existing immunology franchise.

Commercial strategy and market expansion

• Eight approved products in commercial stage, with three to four new launches expected in 2025-2026.

• Vyvgart is a key growth driver, with strong uptake in gMG and CIDP, and over 10,000 patients treated in China.

• KarXT (Cobenfy) for schizophrenia and bemarituzumab for gastric cancer expected to be major contributors.

• TTFields therapy approved for non-small cell lung cancer and showing benefit in pancreatic cancer; China submissions planned.

• Focused sales strategy leverages concentrated therapeutic areas, enabling efficient coverage with existing teams.